MORRISTOWN, N.J. & MILAN--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., and Edmond Pharma S.r.l. today announced that they have entered into a definitive agreement for Alitair Pharmaceuticals to license Erdosteine, a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties, from Edmond Pharma for development as an orphan drug in the United States and Canada. Financial terms of the agreement were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
